To develop MS drugs, MS Pharma split MS into liittle pieces to make it easier to get regulatory approval for treatments….It was successful in that MS drugs appeared in the 1980s but the down side was that it makes it harder to get approval for use of drug in all of MS, with costly trials in relapsing and progressive MS and active versus non-active progressive MS.
My prediction for the future is that pharma will attempt remove the hatchet that makes MS multiple diseases and will glue it back together so that one drug can be used in all of MS…..The great and the good will be used to give this message to the masses….I can predict who will be supporting that view….Will the regulators buy it?
We have had PIRA (progression independent of relapse activity) created to give the impression that certain treatments inhibit progressive MS. This year at ECTRIMS we had SAW unveiled. It is smouldering ASSociated Worsening…which treatments will stop “smoldering MS”…will they be unveilled at ECTRIMS 2026 in Toronto?
The SAW Index Study…..aims to create an evidence-based framework to identify, assess, and measure SAW (Smouldering associated Worsening) in people living with MS, potentially transforming the current landscape of MS measurement. The research is also being conducted in close consultation with the SAW Index Steering Committee a group of consisting of internationally renowned MS experts, people living with MS and representatives from patient advocacy groups.
I doubt that smouldering MS lesions are truely independent of the drivers or relapsing MS lesions but will 2 become one?….The power of the marketeers may get the spice girls
Source: multiple-sclerosis-research.org